456160 - G2GBIO, Inc.

456160 Summary

Biopharma

Stock Price & Overview

₩37,950 +2,050 (+5.71%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩37,950 ≈ US$27 · Market cap ₩0.6tn (≈ $451m)

456160 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Revenue	0.4	0.8	0.7	0.2
Cost of Revenue	0.5	0.6	0.4	0.2
Gross Profit	-0.0	0.2	0.3	0.0
Selling, General & Administrative	4.1	3.3	2.7	2.0
Operating Income	-12.2	-10.8	-13.1	-11.3
Finance Income	0.8	0.5	3.7	26.9
Finance Costs	0.7	72.9	1.2	0.6
Pretax Income	-12.1	-83.3	-10.5	15.1
Net Income	-12.1	-83.3	-10.5	15.1
Total Comprehensive Income	-12.1	-83.8	-10.4	15.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Assets	67.7	25.3	31.5	25.1
Current Assets	53.3	10.7	15.9	6.1
Cash & Cash Equivalents	8.0	10.0	11.6	4.8
Trade Receivables	1.0	0.2	0.6	0.5
Non-current Assets	14.4	14.6	15.6	19.0
Property, Plant & Equipment	12.8	13.7	14.8	17.8
Intangible Assets	0.4	0.3	0.3	0.2
Total Liabilities	9.4	144.9	69.8	55.1
Current Liabilities	7.3	141.7	66.0	46.4
Non-current Liabilities	2.2	3.2	3.9	8.7
Total Equity	58.3	-119.5	-38.3	-30.0
Share Capital	8.2	0.7	0.7	0.7
Retained Earnings	-141.2	-129.0	-45.6	-35.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Cash from Operating Activities	-13.9	-8.0	-11.0	-8.5
Cash from Investing Activities	-45.1	2.1	-4.0	-5.9
Purchase of Property, Plant & Equipment	0.3	0.6	0.8	5.7
Cash from Financing Activities	57.0	4.2	21.8	10.5
Net Change in Cash	-2.0	-1.6	6.8	-4.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3
Total Revenue	1.6	0.4	0.2	0.1	0.2	0.0	-0.0	0.2
Cost of Revenue	0.9	0.2	0.2	0.2	0.1	0.0	0.0	0.1
Gross Profit	0.7	0.2	0.0	-0.1	0.1	0.0	-0.0	0.1
Selling, General & Administrative	1.8	1.2	1.1	1.3	0.9	0.9	0.9	0.8
Operating Income	-2.7	-3.3	-3.0	-3.6	-2.7	-2.9	-3.3	-2.8
Finance Income	1.7	0.5	0.3	0.2	0.0	0.3	0.0	0.1
Finance Costs	4.7	6.0	0.1	0.1	0.1	0.3	-0.1	0.2
Pretax Income	-5.7	-8.8	-2.8	-3.5	-2.9	-2.9	-3.2	-2.9
Income Tax Expense	-3.3	-3.3	—	—	—	—	—	—
Net Income	-5.7	-5.5	-2.8	-3.5	-2.9	-2.9	-3.2	-2.9
Total Comprehensive Income	-6.4	-5.5	-2.8	-3.5	-3.0	-2.8	-3.2	-2.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3
Total Assets	235.0	236.9	67.7	67.2	19.3	22.3	25.3	28.5
Current Assets	219.7	221.7	53.3	53.1	5.2	7.9	10.7	13.5
Cash & Cash Equivalents	12.1	24.8	8.0	17.0	4.8	7.0	10.0	12.5
Trade Receivables	2.7	2.1	1.0	0.5	0.3	0.3	0.2	0.4
Non-current Assets	15.4	15.2	14.4	14.1	14.0	14.4	14.6	14.9
Property, Plant & Equipment	13.7	13.6	12.8	12.6	12.9	13.3	13.7	14.1
Intangible Assets	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3
Total Liabilities	96.0	92.6	9.4	9.2	9.8	9.8	144.9	145.0
Current Liabilities	92.4	89.5	7.3	6.4	6.7	6.7	141.7	141.2
Non-current Liabilities	3.6	3.0	2.2	2.8	3.1	3.1	3.2	3.8
Total Equity	139.0	144.3	58.3	58.0	9.5	12.4	-119.5	-116.5
Share Capital	8.7	8.7	8.2	2.7	2.2	2.2	0.7	0.7
Retained Earnings	-136.2	-129.8	-141.2	-138.4	-134.8	-131.9	-129.0	-125.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3
Cash from Operating Activities	-1.8	-3.0	-2.9	-6.5	-1.9	-2.7	-1.8	—
Cash from Investing Activities	-11.3	-149.4	-8.9	-35.8	-0.1	-0.2	-0.4	—
Purchase of Property, Plant & Equipment	0.6	0.8	0.2	0.0	0.0	0.1	0.1	—
Cash from Financing Activities	0.3	169.2	2.8	54.5	-0.3	-0.0	-0.3	—
Net Change in Cash	-12.7	16.8	-9.0	12.2	-2.3	-3.0	-2.5	—

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 4 fiscal years and 8 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

456160 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	0.4	-45.0%	+20.7%	—	—
Operating income	-12.2	—	—	—	—
Net income	-12.1	—	—	—	—
EPS	₩-727	—	—	—	—
Operating cash flow	-13.9	—	—	—	—
Shareholders' equity	58.3	—	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

456160 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022
Gross margin	-7.9%	24.8%	41.3%	11.0%
Operating margin	-2,884.2%	-1,399.8%	-1,776.7%	-4,686.5%
Net margin	-2,857.1%	-10,827.3%	-1,417.4%	6,262.7%
Return on equity	—	—	—	—
Return on assets	-26.0%	-292.7%	-37.0%	59.9%
Operating cash flow / revenue	-3,290.5%	-1,036.3%	-1,480.2%	-3,552.1%
Capex / revenue	73.7%	75.1%	108.4%	2,361.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 456160

Symbol	Last Price
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
358570GI Innovation, Inc.	₩8,090 +6.2%
086900Medy-Tox, Inc.	₩69,600 +0.4%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.